These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12781708)

  • 41. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Features of HIV-1 that could influence maternal-child transmission.
    Kliks SC; Wara DW; Landers DV; Levy JA
    JAMA; 1994 Aug; 272(6):467-74. PubMed ID: 8040983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
    Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM
    J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.
    Von Gegerfelt A; Albert J; Morfeldt-Månson L; Broliden K; Fenyö EM
    Virology; 1991 Nov; 185(1):162-8. PubMed ID: 1926772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
    Euler Z; van den Kerkhof TL; van Gils MJ; Burger JA; Edo-Matas D; Phung P; Wrin T; Schuitemaker H
    J Virol; 2012 Feb; 86(4):2045-55. PubMed ID: 22156522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses.
    Hutto C; Zhou Y; He J; Geffin R; Hill M; Scott W; Wood C
    J Virol; 1996 Jun; 70(6):3589-98. PubMed ID: 8648693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of correlation between vertical transmission of HIV-1 and maternal antibody titers against autologous virus in human monocyte-derived macrophages.
    Mabondzo A; Narwa R; Roques P; Gras GS; Hervé F; Parnet-Mathieu F; Lasfargues G; Courpotin C; Dormont D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jan; 17(1):92-4. PubMed ID: 9436766
    [No Abstract]   [Full Text] [Related]  

  • 55. Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children.
    Dispinseri S; Cavarelli M; Tolazzi M; Plebani AM; Jansson M; Scarlatti G
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33799407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of HIV-1 envelope evolution suggests antibody-mediated selection of common epitopes among Chinese former plasma donors from a narrow-source outbreak.
    Andrews SM; Zhang Y; Dong T; Rowland-Jones SL; Gupta S; Esbjörnsson J
    Sci Rep; 2018 Apr; 8(1):5743. PubMed ID: 29636501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
    Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing.
    Carter CC; Wagner GA; Hightower GK; Caballero G; Phung P; Richman DD; Pond SL; Smith DM
    Virology; 2015 Jan; 474():34-40. PubMed ID: 25463602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.
    Bęczkowski PM; Logan N; McMonagle E; Litster A; Willett BJ; Hosie MJ
    J Gen Virol; 2015 Mar; 96(Pt 3):671-680. PubMed ID: 25395594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.
    Mayr LM; Powell RL; Ngai JN; Takang WA; Nádas A; Nyambi PN
    PLoS One; 2012; 7(6):e38989. PubMed ID: 22720009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.